<DOC>
	<DOCNO>NCT01474343</DOCNO>
	<brief_summary>The clinical trial P1-SAF-301 open-label , single arm , monocentric , phase I/II clinical study evaluate tolerance safety intracerebral administration adeno-associated viral vector serotype 10 carry human SGSH SUMF1 cDNAs treatment Sanfilippo type A syndrome The treatment plan consist direct injection investigational medicinal product SAF-301 side brain 6 image-guided track , 2 deposit per track , single neurosurgical session . The primary objective ass tolerance safety associate proposed treatment one-year follow . The secondary objective collect data define exploratory test could become evaluation criterion clinical phase III efficacy study . Four patient include clinical trial follow one year . The enrollment follow-up patient take place Bicêtre Hospital . The Neurosurgery perform Necker-Enfants Malades Hospital . Safety evaluate clinical , radiological biological parameter .</brief_summary>
	<brief_title>Intracerebral Gene Therapy Sanfilippo Type A Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis III</mesh_term>
	<criteria>Age : 18 ( eighteen ) month end 6 ( six ) year Onset clinical manifestation relate MPSIIIA first 5 year life SGSH activity peripheral blood cell / culture fibroblast extract less 10 % control . Patient affiliate French social security assimilate regimen Family understanding procedure inform consent Signed informed consent Vital laboratory parameter within normal range Presence brain atrophy inclusion MRI judge corticodural distance 1cm No independent walking ( Ability walk without help ) Any condition would contraindicate permanently anaesthesia Any permanent medical condition relate MPSIIIA Any vaccination 1 month investigational drug administration Intake aspirin within one month Any medication aim modify natural course MPSIIIA give 6 month vector injection Any condition would contraindicate treatment Prograf® , Modigraf® , Cellcept® Solupred®</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Gene Therapy</keyword>
	<keyword>Adenovirus Associated Vector</keyword>
</DOC>